<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04984577</url>
  </required_header>
  <id_info>
    <org_study_id>NJYK-CPEDRV-II</org_study_id>
    <nct_id>NCT04984577</nct_id>
  </id_info>
  <brief_title>Study of Compound Edaravone Injection for Treatment of Acute Ischemic Stroke</brief_title>
  <official_title>Phase Ⅲ Trial of Compound Edaravone Injection for Treatment of Acute Ischemic Stroke -- a Multi-center, Randomized, Double-blind, Parallel, Multi-doses and Active-controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing Yoko Biomedical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing Yoko Biomedical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to confirm the efficacy of compound Edaravone Injection&#xD;
      via intravenous infusion every 12 hours in the patients with Acute Ischemic Stroke(AIS) in a&#xD;
      double-blind, active-controlled manner. The study is also to examine the safety of compound&#xD;
      Edaravone Injection for the AIS patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of patients with mRS ≤1 on day 90</measure>
    <time_frame>day 90</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes of NIHSS score from baseline on day 14</measure>
    <time_frame>day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients with mRS ≤2 on day 90</measure>
    <time_frame>day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients with NIHSS score 0-1 (including motor function) on day 14, 30, 90</measure>
    <time_frame>day 14, 30, 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients with ADL-BI ≥95 on day 14, 30, 90</measure>
    <time_frame>day 14, 30, 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D score on day 90</measure>
    <time_frame>day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ordinal Distribution of mRS on day 90</measure>
    <time_frame>day 90</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Acute Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Compound Edaravone Injection-Low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Compound Edaravone Injection-High dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Edaravone Injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Injection</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Compound Edaravone Injection-Low dose</intervention_name>
    <description>Compound Edaravone Injection 30mg/dose (Edaravone 30mg, Taurine 600 mg), one dose every 12 hours, continue for 14 days</description>
    <arm_group_label>Compound Edaravone Injection-Low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Compound Edaravone Injection-High dose</intervention_name>
    <description>Compound Edaravone Injection 50mg/dose (Edaravone 50mg, Taurine 1000 mg), one dose every 12 hours, continue for 14 days</description>
    <arm_group_label>Compound Edaravone Injection-High dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Edaravone Injection</intervention_name>
    <description>Edaravone Injection 30mg/dose, one dose every 12 hours, continue for 14 days</description>
    <arm_group_label>Edaravone Injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo injection</intervention_name>
    <description>Placebo injection, one dose every 12 hours, continue for 14 days</description>
    <arm_group_label>Placebo Injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Hospitalized patients, diagnosed of ischemic stroke;&#xD;
&#xD;
          -  Onset of stroke is less than or equal to 48 hours;&#xD;
&#xD;
          -  There are clear signs of neurological deficit: 4≤NIHSS score≤24, and also, the sum of&#xD;
             NIHSS score for the upper limb and the lower limb is greater than or equal to 2;&#xD;
&#xD;
          -  Patients signed written inform consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cranial CT scan finds intracranial bleeding disorders: hemorrhagic stroke, epidural&#xD;
             hematoma, intracranial hematoma, intraventricular hemorrhage, subarachnoid hemorrhage;&#xD;
&#xD;
          -  Iatrogenic stroke;&#xD;
&#xD;
          -  Severe disturbance of consciousness: NIHSS category 1a for consciousness is greater&#xD;
             than 1；&#xD;
&#xD;
          -  The mRS score prior to this onset is greater than 1;&#xD;
&#xD;
          -  Transient ischemic attack (TIA);&#xD;
&#xD;
          -  SBP after blood pressure control is still greater than or equal to 220 mmHg, or DBP&#xD;
             after blood pressure control is still greater than or equal to 120 mmHg;&#xD;
&#xD;
          -  Patients with severe mental disorders and dementia;&#xD;
&#xD;
          -  ALT or AST is greater than 2.0×ULN; Serum Creatinine (SCr) is greater than 1.5×ULN or&#xD;
             Creatinine Clearance (CrCl) is less than 50 ml/min;&#xD;
&#xD;
          -  Therapeutic neuroprotective agents have been applied after onset of stroke, including&#xD;
             commercially available edaravone, nimodipine, ganglioside, citicoline, piracetam,&#xD;
             butyl benzene peptides, Urinary Kallidinogenase;&#xD;
&#xD;
          -  Thrombectomy or interventional therapy has been applied or planned after this onset;&#xD;
&#xD;
          -  Patients with malignant tumors or receiving concurrent antitumor treatment;&#xD;
&#xD;
          -  Patients with severe systemic disease, life expectancy is less than 90 days;&#xD;
&#xD;
          -  Allergic to edaravone , taurine or related excipients;&#xD;
&#xD;
          -  Pregnant or lactating women;&#xD;
&#xD;
          -  Have major surgery within 4 weeks before enrollment and not recovered enough to start&#xD;
             the study;&#xD;
&#xD;
          -  Participated in other clinical studies within 30 days before randomization;&#xD;
&#xD;
          -  The investigators consider the patients are not suitable for this trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Beijing Tiantan Hospital，Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yongjun Wang, professor</last_name>
      <phone>13911172565</phone>
      <email>yongjunwang111@aliyun.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 29, 2021</study_first_submitted>
  <study_first_submitted_qc>July 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2021</study_first_posted>
  <last_update_submitted>July 29, 2021</last_update_submitted>
  <last_update_submitted_qc>July 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edaravone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

